多激酶抑制剂/仑伐替尼在同时性/异时性合并放射性抵抗分化型甲状腺癌的癌症患者中的应用。
Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.
机构信息
Endocrinology and Nutrition Department, General University Hospital Gregorio Maranon, Madrid, Spain.
出版信息
Cancer Med. 2022 Oct;11 Suppl 1(Suppl 1):26-32. doi: 10.1002/cam4.5107.
This review focuses on patients with differentiated thyroid carcinoma (DTC) associated with multiple primary malignant neoplasm (MPMN) treated by multikinase inhibitors (MKIs) as systemic treatment for advanced disease. Despite the increasing frequency of MPMNs (many at an advanced stage) and the usefulness of MKIs for multiple metastatic cancers, published data on the management of MPMN and MKI therapies in this scenario are scarce. There are infrequent descriptions of patients with advanced MPMN treated with MKIs, but only a few have described advanced DTC. The management of MPMNs, including DTC and its particular circumstances, is reviewed, focusing on the evidence for MKI therapies. Some considerations for MPMN patients with advanced DTC are discussed, with the intention of helping physicians make decisions in these challenging situations and improving treatment and patient outcomes.
这篇综述主要关注的是患有甲状腺分化癌（DTC）并伴有多种原发性恶性肿瘤（MPMN）的患者，他们接受了多激酶抑制剂（MKIs）作为晚期疾病的系统治疗。尽管 MPMN（许多处于晚期）的发病率不断增加，以及 MKI 对多种转移性癌症的有效性，但在这种情况下，关于 MPMN 和 MKI 治疗管理的文献数据仍然很少。只有少数文献描述了晚期 MPMN 患者接受 MKI 治疗的情况，而且这些描述也很罕见。本文回顾了 MPMN 的管理，包括 DTC 及其特殊情况，并重点介绍了 MKI 治疗的证据。还讨论了一些晚期 DTC 伴 MPMN 患者的注意事项，旨在帮助医生在这些具有挑战性的情况下做出决策，并改善治疗和患者的预后。
Zotero 插件